AACR logo

More articles from Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts

Abstract A019: Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies
Jun Tang, Laura Pearce, Jill O'Donnell-Tormey, Vanessa M. Hubbard-Lucey

Cancer Immunology Research Feb 2019, 7 (2 Supplement) A019; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A019
Abstract A004: HER2 cancer vaccine phase I clinical trial shows clinical benefit in 54% of evaluable patients
Jay A. Berzofsky, Lauren V. Wood, Hoyoung Maeng, Jane Trepel, David Stroncek, John C. Morris

Cancer Immunology Research Feb 2019, 7 (2 Supplement) A004; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A004
Abstract A011: First-in-man clinical trial of intratumoral injection of Clostridiumnovyi-NT spores in patients with treatment-refractory advanced solid tumors: Safety, activity, and immune responses
Filip Janku, Mrinal Gounder, Abdul Mohammad Pezeshki, Ravi Murthy, Andrea Wang-Gillam, Dale Shepard, David S. Hong, Sarina A. Piha-Paul, Anjali Raina, Alexey A. Leontovich, Gary DeCrescenzo, Brent L. Kreider, David Tung, Mary Varterasian, Halle H. Zhang, Khashayarsha Khazaie

Cancer Immunology Research Feb 2019, 7 (2 Supplement) A011; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A011
Abstract A015: Cellular immunomonitoring for personalized adoptive cellular therapy trial ACTolog® (IMA101-101)
Regina Mendrzyk, Alexander Ulges, Thorsten Demberg, Geoffrey Stephens, Carsten Reinhardt, Steffen Walter, Dominik Maurer

Cancer Immunology Research Feb 2019, 7 (2 Supplement) A015; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A015
Abstract A005: A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers
Ana B. Blazquez, Alex Rubinsteyn, Julia Kodysh, John P. Finnigan, Thomas Marron, Rachel L. Sabado, Marcia Meseck, Timothy J. O'Donnell, Jeffrey Hammerbacher, Michael Donovan, John Holt, Milind Mahajan, John Mandeli, Krysztof Misiukiewicz, Eric M. Genden, Brett A. Milles, Hooman Khorasani, Peter R. Dottino, Hanna Irie, Amy B. Tiersten, Elisa R. Port, Andrea S. Wolf, Hern J. Cho, Ashutosh Tewari, Samir S. Parekh, Sujit Nair, Matthew D. Galsky, William K. Oh, Sacha Gnjatic, Eric E. Schadt, Phillip A. Friedlander, Nina Bhardwaj

Cancer Immunology Research Feb 2019, 7 (2 Supplement) A005; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A005
Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC)
Dmitriy Zamarin, Kunle Odunsi, Brian Slomovitz, Vanessa M. Hubbard-Lucey, Danielle McCabe, Lisa Shohara, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Anne-Kirsti Aksnes, Lukasz Kuryk, Ralph Venhaus

Cancer Immunology Research Feb 2019, 7 (2 Supplement) A022; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A022
Abstract A021: Vaccination with autologous, nonattenuated, live glioblastoma cells induces potent peripheral and intratumoral anti-tumoral responses: A first-in-human study
Ilan Volovitz, Nati Shapira, Rachel Grossman, Zvi Ram

Cancer Immunology Research Feb 2019, 7 (2 Supplement) A021; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A021
Abstract A008: Neoadjuvant nivolumab, gemcitabine and cisplatin in muscle-invasive bladder cancer: Study update
Shilpa Gupta, Christopher J. Weight, Neeraj Agarwal, Sumati Gupta, Badrinath Konety, Ewan Gibb, Elai Davicioni, Bharat Thyagarajan, Guru Sonpavde

Cancer Immunology Research Feb 2019, 7 (2 Supplement) A008; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A008
Abstract A001: Phase I study of vaccine therapy with a cocktail of peptides for pediatric patients with refractory solid tumors
Yu Akazawa, Ako Hosono, Toshiaki Yoshikawa, Hide Kaneda, Junichi Hara, Yoshiaki Kinoshita, Kenichi Kohashi, Atsushi Manabe, Yoko Shioda, Kayoko Shoda, Manami Shimomura, Shoichi Mizuno, Yasunari Nakamoto, Tetsuya Nakatsura

Cancer Immunology Research Feb 2019, 7 (2 Supplement) A001; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A001
Abstract A012: SV-BR-1-GM, a whole-cell targeted immunotherapy for advanced breast cancer: Pharmacodynamic markers of response
Markus D. Lacher, Sanne Graeve, Vivekananda (Vivek) Sunkari, Daniel L. Adams, Cha-Mei Tang, Pete Amstutz, Charles L. Wiseman, George E. Peoples, William V. Williams

Cancer Immunology Research Feb 2019, 7 (2 Supplement) A012; DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A012

Main menu

User menu

Search

More articles from Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts

Pages

Articles

Info for

About Cancer Immunology Research